期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 15, 页码 -出版社
MDPI
DOI: 10.3390/ijms23158541
关键词
molecular oncology; molecular pathology; PD-L1; immune-checkpoint inhibitors; biomarkers
资金
- Monitoraggio ambientale, studio ed approfondimento della salute della popolazione residente in aree a rischio-In attuazione della D.G.R. Campania [180/2019]
- POR Campania FESR 2014-2020 Progetto Sviluppo di Approcci Terapeutici Innovativi per patologie Neoplastiche resistenti ai trattamenti-SATIN
This study fills the information gap regarding the role of ICIs in NSCLC patients with other driver mutations and provides a molecular landscape of clinically relevant oncogenic drivers in PD-L1 positive NSCLC patients. The results demonstrate that some patients with a PD-L1 tumor proportion score of 50% or higher and concomitant gene alterations may benefit from ICIs treatment, even in the presence of a KRAS gene alteration.
Background: Immune-checkpoint inhibitors (ICIs) have increased and improved the treatment options for patients with non-oncogene-addicted advanced stage non-small cell lung cancer (NSCLC). However, the role of ICIs in oncogene-addicted advanced stage NSCLC patients is still debated. In this study, in an attempt to fill in the informational gap on the effect of ICIs on other driver mutations, we set out to provide a molecular landscape of clinically relevant oncogenic drivers in programmed death-ligand 1 (PD-L1) positive NSCLC patients. Methods: We retrospectively reviewed data on 167 advanced stage NSCLC PD-L1 positive patients (>= 1%) who were referred to our clinic for molecular evaluation of five driver oncogenes, namely, EGFR, KRAS, BRAF, ALK and ROS1. Results: Interestingly, n = 93 (55.7%) patients showed at least one genomic alteration within the tested genes. Furthermore, analyzing a subset of patients with PD-L1 tumor proportion score (TPS) >= 50% and concomitant gene alterations (n = 8), we found that n = 3 (37.5%) of these patients feature clinical benefit with ICIs administration, despite the presence of a concomitant KRAS gene alteration. Conclusions: In this study, we provide a molecular landscape of clinically relevant biomarkers in NSCLC PD-L1 positive patients, along with data evidencing the clinical benefit of ICIs in patient NSCLC PD-L1 positive alterations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据